Table 3. Final parsimonious multivariable models for recurrence-free, cancer-specific, and overall survival.
Parameter | HR (95% CI) | P-value |
---|---|---|
Model for recurrence-free survivala | ||
T-stage, pT3-4 vs pT0-2 | 1.58 (1.03–2.42) | 0.03 |
N-stage, N+ vs N0 | 2.15 (2.82–2.53) | <0.0001 |
Lymphovascular invasion | 1.72 (1.04–2.86) | 0.03 |
Positive surgical margin | 2.16 (1.42–3.28) | <0.001 |
Neutrophil–lymphocyte ratio, per 1-unit increaseb | 1.52 (1.17–1.98) | 0.002 |
Model for cancer-specific survivalc | ||
T-stage, pT3-4 vs pT0-2 | 1.67 (1.07–2.62) | 0.02 |
N-stage, N+ vs N0 | 2.13 (1.27–3.57) | 0.004 |
Lymphovascular invasion | 1.75 (0.94–3.28) | 0.08 |
Positive surgical margin | 1.82 (0.88–3.79) | 0.11 |
Haemoglobin (per 1 g/l increase) | 0.91 (0.86–0.95) | <0.001 |
Neutrophil–lymphocyte ratio, per 1-unit increaseb | 1.47 (1.20–1.80) | <0.001 |
Model for overall survivald | ||
Age, per 1 year increase | 1.03 (1.01–1.04) | 0.008 |
Charlson co-morbidity index, per 1-point increase | 1.16 (1.03–1.32) | 0.01 |
T-stage, pT3-4 vs pT0-2 | 1.42 (0.83–2.45) | 0.20 |
N-stage, N+ vs N0 | 1.55 (1.12–2.14) | 0.008 |
Lymphovascular invasion | 1.74 (1.03–2.93) | 0.04 |
Positive surgical margin | 1.86 (0.90–3.82) | 0.09 |
Haemoglobin, per 1 g/dl increase | 0.90 (0.88–0.93) | <0.001 |
Neutrophil–lymphocyte ratio, per 1-unit increaseb | 1.56 (1.16–2.10) | 0.004 |
Abbreviations: AIC=Akaike Information Criterion; CI=confidence interval; HR=hazard ratio.
Likelihood ratio omnibus test: χ2=84.8, dF=5, P<0.001; AIC=1407.0.
Variable was log-transformed, and therefore hazard ratios represent effect per 1 log-unit.
Likelihood ratio omnibus test: χ2=68.9, dF=6, P<0.001; AIC=1101.6.
Likelihood ratio omnibus test: χ2=111.0, dF=8, P<0.001; AIC=1780.7.